Commercial Approvals
Validated Commercial Therapy in China Across Diverse Autoimmune Diseases
2023 – Systemic Lupus Erythematosus (SLE)
2024 – Rheumatoid Arthritis (RA)
2025 – Myasthenia Gravis (MG)
The Medicine
Meets the Moment
Unprecedented Efficacy In China
Across Autoimmune Diseases
3
2
BLA Submissions Approvals
Poised to Further Expand Telitacicept Footprint in Large, Underserved Diseases in China
Filed 2025 – Sjögrens Disease (pSD)
Filed 2025 – IgA Nephropathy (IgAN)
3
Best-In-Disease
Unique Dual BAFF/APRIL Inhibition Drives Superior Clinical Benefit
Systemic Lupus Erythematosus
Myasthenia Gravis
Sjögrens Disease
Tens of Thousands
Patients Treated Commercially in China
A Pipeline of Autoantibody-Driven
Diseases & Blockbuster Opportunities
Sjögren’s Disease
290,000
Potential Patients in the US Alone
SLE
240,000
Potential Patients in the US Alone
ANCA-AAC
140,000
Potential Patients in the US Alone
Lupus Nephritis
105,000
Potential Patients in the US Alone
Myasthenia Gravis
90,000
Potential Patients in the US Alone
Membraneous Nephropathy
70,000
Potential Patients in the US Alone
ITP
65,000
Potential Patients in the US Alone
Bullous Pemphigoid
40,000
Potential Patients in the US Alone
CIDP
30,000
Potential Patients in the US Alone
NMOSD
25,000
Potential Patients in the US Alone
IgG4-RD
20,000
Potential Patients in the US Alone
Total Addressable Patients
1,000,000+
Potential Patients in the US Alone
1,000,000+
Potential Patients in the US Alone
